Ефективність терапії статинами у жінок

Автор(и)

  • V. I. Volkov ГУ «Национальный институт терапии имени Л.Т. Малой НАМН Украины», Харьков, Україна
  • A. S. Isaieva ГУ «Национальный институт терапии имени Л.Т. Малой НАМН Украины», Харьков, Україна

DOI:

https://doi.org/10.37987/1997-9894.2015.2(188).222515

Ключові слова:

жінки, терапія, статини, первинна профілактика, вторинна профілактика

Анотація

У статті наведено аналіз результатів численних міжнародних досліджень щодо ефективності терапії статинами у жінок різних вікових груп. Показано ефективність застосування статинів у жінок з метою вторинної профілактики серцево-судинних ускладнень, в той час як щодо первинної профілактики залишається багато невирішених питань.

Біографії авторів

V. I. Volkov, ГУ «Национальный институт терапии имени Л.Т. Малой НАМН Украины», Харьков

В.И. ВОЛКОВ, д. мед. н.

A. S. Isaieva, ГУ «Национальный институт терапии имени Л.Т. Малой НАМН Украины», Харьков

А.С. Ісаєва

Посилання

Scandinavian Simvastatin Survival Study Group et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) // Lancet. – 1994. – Т. 344, №8934. – С. 1383–1389.

Shepherd J. et al. Prevention of coronary heart disease with pravastatin in men with hyper-cholesterolemia // New Engl. J. of Medicine. – 1995. – Т. 333, №20. – С. 1301–1308.

Sacks F.M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels // New Engl. J. of Medicine. – 1996. – Т. 335, №14. – С. 1001–1009.

Downs J.R. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS // JAMA. – 1998. – Т. 279, №20. – С. 1615–1622.

Hague W. et al. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study // Am. Heart J. – 2003. – Т. 145, №4. – С. 643–651.

Schwartz G.G. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial // JAMA. – 2001. – Т. 285, №13. – С. 1711–1718.

Yusuf S. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary // Lancet. – 2002. – Т. 360, №9326. – С. 7–22.

Ridker P.M. The JUPITER trial results, controversies, and implications for prevention // Circulation: Cardiovascular Quality and Outcomes. – 2009. – Т. 2, №3. – С. 279–285.

Pedersen T.R. et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study // Am. J. of Cardiology. – 2004. – Т. 94, №6. – С. 720–724.

Wenger N.K. et al. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study // Heart. – 2008. – Т. 94, №4. – С. 434–439.

Sever P.S., Poulter N.R., Dahlof B. et al., the ASCOT investigators: Reduction in cardiovascular events with atorvastatin in 2,532 patients with Type 2 diabetes // Diabetes Care. – 2005. – Т. 28. – С. 1151–1157.

Brugts J.J., Yetgin T., Hoeks S.E. et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials // BMJ. – 2009. – Т. 338.

Protocol No. A2581051: Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women: a randomized evaluation of atorvastatin versus placebo (CASHMERE). – www.clinicaltrials.gov/ct/show/NCT00163163?order=1 (Accessed 29 March 2008).

Nakaya N. et al. Low-Dose Pravastatin and Age-Related Differences in Risk Factors for Cardiovascular Disease in Hypercholesterolaemic Japanese // Drugs & Aging. – 2011. – Т. 28, №9. – С. 681–692.

Miettinen T.A. et al. Cholesterol-Lowering Therapy in Women and Elderly Patients With Myocardial Infarction or Angina Pectoris Findings From the Scandinavian Simvastatin Survival Study (4S) // Circulation. – 1997. – Т. 96, №12. – С. 4211–4218.

Walsh J.M.E., Pignone M. Drug treatment of hyperlipidemia in women // JAMA. – 2004. – Т. 291, №18. – С. 2243–2252.

Mora S. et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials //Circulation. – 2010. – Т. 121, №9. – С. 1069–1077.

Lewis S.J. et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial // J. of the Am. College of Cardiology. – 1998. – Т. 32, №1. – С. 140–146.

Hague W., Forder P., Simes J. et al. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study // Am. Heart J. –2003 Apr. – Т. 145 (4). – С. 643–651.

Shepherd J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial // Lancet. – 2002. – Т. 360, №9346. – С. 1623–1630.

Petretta M., Costanzo P., Perrone-Filardi P., Chiariello M. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis // Int. J. of Cardiology. – 2010. – Т. 138 (1). – С. 25–31.

Gutierrez J. et al. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis // Archives of Internal Medicine. – 2012. – Т. 172, №12. – С. 909–919.

Kostis W.J. et al. Meta-analysis of statin effects in women versus men // J. of the Am. College of Cardiology. – 2012. – Т. 59, №6. – С. 572–582.

Мітченко О.І. Методичні рекомендації Української асоціації кардіологів. Дисліпідемії : діагностика, профілактика та лікування. – К., 2011. – С. 1–48.

Reiner Z. et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart J. – 2011. – Т. 32, №14. – С. 1769–1818.

Santos R.D. et al. Low-and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2 // Am. Heart J. – 2009. – Т. 158, №5. – С. 860–866.

Victor B.M. et al. Gender Differences in Achieving Optimal Lipid Goals in Patients With Coronary Artery Disease // Am. J. of Cardiology. – 2014. – Т. 113, №10. – С. 1611–1615.

Singh M. et al. Time Trends of Gender-Based Differences in Lipid Goal Attainments During Secondary Prevention of Coronary Artery Disease: Results of a 5-Year Survey // Am. J. of Therapeutics. – 2013. – Т. 20, №6. – С. 613–617.

Reibis R.K. et al. Elevated risk profile of women in secondary prevention of coronary artery disease: a 6-year survey of 117,913 patients // J. of Women's Health. – 2009. – Т. 18, №8. – С. 1123–1131.

Schrott H.G., Bittner, V., Vittinghoff E. et al. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/Progestin Replacement Study (HERS) // JAMA. – 1997. – Т. 277, №16. – С. 1281–1286.

Dallongevillle, J., De Bacquer D., Heidrich J. et al. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event // Heart. – 2010. – Т. 96, №21. – С. 1744–1749.

Chen C.Y., Chuang S.Y., Fang C.C. et al. Gender difference in statin intervention on blood lipid control among patients with coronary heart disease // Int. J. of Gerontology. – 2013. – Т. 7, №2. – С. 116–121.

Takahashi E., Moriyama K., Yamakado M. Status of dyslipidemia treatment in Japanese adults: an analysis of the 2009 Japan Society of Ningen Dock database // Internal Medicine (Tokyo, Japan). – 2012. – Т. 52, №3. – С. 295–301.

Merz C.N.B. The Yentl syndrome is alive and well // Eur. Heart J. – 2011. – Т. 32, №11. – С. 1313–1315.

Persson L., Henriksson P., Westerlund E. et al. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp (a) or bile acid synthesis in women // Arteriosclerosis, Thrombosis, and Vascular Biology. – 2012. – Т. 32, №3. – С. 810–814.

De Marinis E., Martini C., Trentalance A., Pallottini V. Sex differences in hepatic regulation of cholesterol homeostasis // J. of Endocrinology. – 2008. – Т. 198, №3. –С. 635–643.

Saltiki K., Doukas C., Kanakakis J. et al. Severity of cardiovascular disease in women: relation with exposure to endogenous estrogen // Maturitas. – 2006. – Т. 55, №1. – С. 51–57.

Harlow S.D., Gass M., Hall J.E. et al.; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging // Menopause. – 2012. – Т. 19 (4). – С. 387–395.

Chu M.C., Rath K.M., Huie J., Taylor H.S. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk // Hum. Reprod. – 2003. – Т. 18 (8). – С. 1570–1573.

Crandall C.J., Barrett-Connor E. Endogenous sex steroid levels and cardiovascular disease in relation to the menopause: a systematic review // Endocrinol. Metab. Clin. North Am. – 2013. – Т. 42 (2). – С. 227–253.

Derby C.A., Crawford S.L., Pasternak R.C. et al. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation // Am. J. Epidemiol. – 2009. – Т. 169 (11). – С. 1352–1361.

Greenfield J.R., Samaras K., Campbell L.V. et al. Physical activity reduces genetic susceptibility to increased central systolic pressure augmentation: a study of female twins // J. of the Am. College of Cardiology. – 2003. – Т. 42, №2. – С. 264–270.

De Villiers T.J., Gass M.L.S., Haines C.J. et al. Global consensus statement on menopausal hormone therapy // Climacteric. – 2013. – Т. 16, №2. – С. 203–204.

Prentice R.L. Postmenopausal Hormone Therapy and the Risks of Coronary Heart Disease, Breast Cancer, and Stroke // Seminars in Reproductive Medicine. – 2014. – Т. 32, №6. – С. 419–425.

Writing Group for the Women's Health Initiative Investigators et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial // JAMA. – 2002. – Т. 288, №3. – С. 321–333.

Rossouw J.E., Anderson G.L., Prentice R.L. et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial // JAMA. – 2002. – Т. 288, №3. – С. 321–333.

Manson J.E., Chlebowski R.T., Stefanick M.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials // JAMA. – 2013. – Т. 310, №13. –С. 1353–1368.

Gurney E.P., Nachtigall M.J., Nachtigall L.E., Naftolin F. The Women's Health Initiative trial and related studies: 10 years later: A clinician's view // J. of Steroid Biochemistry and Molecular Biology. – 2014. – Т. 142. – С. 4–11.

Lacey Jr J.V. The WHI ten year's later: An epidemiologist's view // J. of Steroid Biochemistry and Molecular Biology. – 2014. – Т. 142. – С. 12–15.

Dessapt A.L., Gourdy P. Menopause and cardiovascular risk // J. de Gynecologie, Obstetrique et Biologie de la Reproduction. – 2012. – Т. 41, №7 (Suppl). – С. F13–19.

Schnatz P.F. Hormonal therapy: does it increase or decrease cardiovascular risk? // Obstetrical & Gynecological Survey. – 2006. – Т. 61, №10. – С. 673–681.

Grady D., Herrington D., Bittner V. et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) // JAMA. – 2002. – Т. 288, №1. – С. 49–57.

Paggi P., Davidson M., Callister T.Q. et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women beyond endorsed lipid lowering with EBT scanning (BELLES) // Circulation. – 2005. – Т. 112, №4. – С. 563–571.

Herrington D.M. et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS) // Circulation. – 2002. – Т. 105, №25. – С. 2962–2967.

Li L., Sun T., Zhang P. et al. Statins for primary prevention of venous thromboembolism //Cochrane Database Syst. Rev. – 2011. – Т. 12.

Hsia J., Klouj A., Prasad A. et al. Progression of coronary calcification in healthy postmenopausal women // BMC cardiovascular disorders. – 2004. – Т. 4, №1. – С. 21.

Pellegrini C.N., Vittinghoff E., Lin F. et al. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial // Heart. – 2009. – Т. 95, №9. – С. 704–708.

Lobo R.A. Postmenopausal hormones and coronary artery disease: potential benefits and risks // Climacteric. – 2007. – Т. 10, №S2. – С. 21–26.

Ozsener S., Sendag F., Koc T. et al. Comparison of Continuous Combined Hormone Replacement Therapy, HMG-CoA Reductase Inhibitor and Combined Treatment for the Management of Hypercholesterolemia in Postmenopausal Women // J. of Obstetrics and Gynaecology Research. – 2001. – Т. 27, №6. – С. 353–358.

Shepherd J., Packard C., Walker J. et al. Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy // Current Med. Research and Opinion. – 2004. – Т. 20, №10. – С. 1571–1578.

Koh K.K., Schenke W.H., Waclawiw M.A. et al. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women // Circulation. –2002. – Т. 105, №13. – С. 1531–1533.

Sbarouni E., Kyriakides Z.S., Kremastinos D.T. Effect of simvastatin on serum C-reactive protein during hormone replacement therapy // Am. J. of Cardiology. – 2004. – Т. 93, №2. – С. 217–218.

Dobrzycka B., Dobrzycki S., Lenczewski A. et al. Effects of simvastatin only or in combination with continuous combined hormone replacement therapy on lipid levels in hypercholesterolemic women // Ginekologia Polska. – 2003. – Т. 74, №9. – С. 937–942.

##submission.downloads##

Опубліковано

2015-02-28

Як цитувати

Volkov, V. I., & Isaieva, A. S. (2015). Ефективність терапії статинами у жінок. Ліки України, (2(188), 7–12. https://doi.org/10.37987/1997-9894.2015.2(188).222515

Номер

Розділ

ЛЕКЦІЇ, ОГЛЯДИ